Guido J Tricot

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
    Guido Tricot
    The Myeloma and Transplantation Research Center and the Division of Biometry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 116:211-7. 2002
  2. ncbi Treatment advances in multiple myeloma
    Guido Tricot
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 125:24-30. 2004
  3. ncbi What is the significance of molecular remission in multiple myeloma?
    Guido J Tricot
    Clinical Research in the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 5:91-5. 2007
  4. ncbi Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
  5. ncbi Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
    Jumei Shi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 111:1309-17. 2008
  6. ncbi New insights into role of microenvironment in multiple myeloma
    Guido J Tricot
    Arkansas Cancer Research Center, Little Rock, USA
    Int J Hematol 76:334-6. 2002

Research Grants

  1. Gene expression profiling vs MRD assessment in Myeloma
    Guido Tricot; Fiscal Year: 2007

Detail Information

Publications6

  1. ncbi Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
    Guido Tricot
    The Myeloma and Transplantation Research Center and the Division of Biometry, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 116:211-7. 2002
    ..or = 7 years and re-establishment of a monoclonal gammopathy of undetermined significance (MGUS) phase in those with persistent evidence of disease post transplantation, but without disease progression > or = 7 years...
  2. ncbi Treatment advances in multiple myeloma
    Guido Tricot
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 125:24-30. 2004
  3. ncbi What is the significance of molecular remission in multiple myeloma?
    Guido J Tricot
    Clinical Research in the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 5:91-5. 2007
    ..The time to disease progression of such patients appears to be significantly longer compared to that of patients not achieving a molecular CR...
  4. ncbi Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
    ..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
  5. ncbi Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
    Jumei Shi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 111:1309-17. 2008
    ..Our findings have clear therapeutic implications for MM and other NK cell-sensitive malignancies in the context of both allogeneic and autologous adoptively transferred NK cells...
  6. ncbi New insights into role of microenvironment in multiple myeloma
    Guido J Tricot
    Arkansas Cancer Research Center, Little Rock, USA
    Int J Hematol 76:334-6. 2002
    ..It remains unclear what specific gene confers the poor prognosis to patients with deletion 13. The issues of bone disease, drug resistance and cytogenetics will be addressed in detail during this presentation...

Research Grants1

  1. Gene expression profiling vs MRD assessment in Myeloma
    Guido Tricot; Fiscal Year: 2007
    ..These findings can serve as a model for treatment approaches in other chronic lymphoproliferative and myeloproliferative malignancies, which exhibit a similar disease progression. ..